CBB Seminars

Computational Biology Branch (CBB) is the research branch of the National Center for Biotechnology Information (NCBI), National Library of Medicine (NLM), National Institutes of Health (NIH).

We hold weekly seminars by CBB members each Tuesday at 11 AM in the Building 38A B2 NCBI Library. Visitors' presentations usually take place in the same room, but are scheduled on a different day of the week. If scheduling a visitor's presentation, please don't forget to book a seminar room.

To schedule a seminar, please click on the appropriate date in the calendar.

Contact Ivan Ovcharenko with questions or if you need help scheduling a seminar.

Upcoming Seminars

Yoo Ah KimMay 31, 2016 at 11:00
Mutual Exclusivity Analysis in Cancer Mutations
“Mutual exclusivity is a widely recognized property of many cancer drivers. Knowledge about these relationships can provide important insights into cancer drivers, cancer-driving pathways, and cancer subtypes. It can also be used to predict new functional interactions between cancer driving genes and uncover novel cancer drivers. The data gathered by the Pan-Cancer initiative has created an unprecedented opportunity for illuminating common features across different cancer types. However, separating tissue-specific features from across cancer signatures has proven to be challenging. In the first part of this talk, I will introduce a classification of mutual exclusivity in Pan-cancer analysis into three classes: within tissue type exclusivity, across tissue type exclusivity and between tissue type exclusivity. We combined across-cancer mutual exclusivity with interactions data to uncover pan-cancer dysregulated pathways. Our method, Mutual Exclusivity Module Cover (MEMCover) not only identified previously known Pan-Cancer dysregulated subnetworks but also uncovered novel subnetworks whose across cancer role has not been appreciated well before. Currently, most of mutual exclusivity analyses are preformed focusing on a limited set of genes in part due to the computational cost required to rigorously compute p-values. In the second part of my talk, I will discuss WeSME, which is a new, efficient method to estimate p-values while controlling the mutation rates of individual patients and genes similar to the permutation test. A comprehensive mutual exclusivity analysis allowed us to uncover mutually exclusive pairs, some of which may have relatively low mutation rates. These pairs often included likely cancer drivers that have been missed in previous analyses. More importantly, our results demonstrated that mutual exclusivity can also provide information that goes beyond the interactions between cancer drivers and can, for example, elucidate different mutagenic processes in different cancer groups. In particular, including frequently mutated, long genes such as TTN in our analysis allowed us to observe interesting patterns of APOBEC activity in breast cancer and identify a set of related driver genes that are highly predictive of patient survival. “

Minghui LiJune 7, 2016 at 11:00
MutaBind estimates and interprets the effects of sequence variants on protein-protein interactions
Chih-Hsuan WeiJune 9, 2016 at 11:00
TBD